$100M in Medical Debt Eliminated thanks to Philanthropic Gift
RIP Medical Debt Collaborates with Ryan "Jume" Jumonville to Spread Love
This medical debt was abolished as a charitable act; eliminating any potential tax consequences for recipients. Medical expenses are the leading cause of bankruptcy in the
RIP Medical Debt is a not-for-profit, national charity that raises funds from donors and uses those funds to acquire and abolish medical debt. Since inception in 2014 nearly
RIP Medical Debt is committed to relieving people of the burden of medical debt to enhance their economic opportunities and to enable them to live healthier lives. RIP's criteria for debt relief are those individuals who are four times or below the federal poverty level or those with medical debt that is 5% or more of their gross annual income. Medical debt relief cannot be requested and is source-based.
About Philanthropist Ryan "Jume" Jumonville
Jumonville has a passion for philanthropy. He is primarily focused on children's healthcare and was the fastest to reach the Million Miracle Club for Children's Miracle Network Hospitals. He has also provided scholarships for children of fallen
About RIP Medical Debt
Since being founded in 2014 by two former debt collectors, RIP Medical Debt has acquired — and abolished — more than
View original content:https://www.prnewswire.com/news-releases/100m-in-medical-debt-eliminated-thanks-to-philanthropic-gift-301803358.html
SOURCE Ryan D. “Jume” Jumonville
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- David Lozano Wins King of the Mountains at the Philadelphia Cycling Classic
- PG&E Statement on Senate Bill 492
- HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer i
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Bankruptcy, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share